Adalimumab treatment of resistant chondrocalcinosis; [Tratamiento con adalimumab de la condrocalcinosis resistente]
Küçük Resim Yok
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Ediciones Doyma, S.L.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
In this article, we present a case of resistant chondrocalcinosis who had a good response with 40 mg subcutaneous adalimumab. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in CPPD. © 2024 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Açıklama
Anahtar Kelimeler
Adalimumab, Calcium pyrophosphate, Chondrocalcinosis, Tumor necrosis factor-alpha
Kaynak
Reumatologia Clinica
WoS Q Değeri
Scopus Q Değeri
Q3
